HUMAN PAPILLOMAVIRUS AS A PUBLIC HEALTH CHALLENGE: THE ROLE OF VACCINATION AND SYSTEMIC CARE IN THE ELIMINATION OF HPV-RELATED DISEASES – A REVIEW OF CURRENT RECOMMENDATIONS AND IMPLEMENTATION CHALLENGES
Abstract
The Human Papillomavirus (HPV) represents a global public health concern that can significantly impact both mental well-being and lead to the development of various diseases, including life-threatening malignancies. A proactive and informed approach is crucial in limiting the spread of the virus, which is why comprehensive education - beginning in early school years and continuing through medical training and ongoing professional development for physicians, nurses and other healthcare workers – is essential. Currently, there is no approved targeted therapy for HPV infection. Available treatment options focus primarily on managing HPV-associated lesions rather than eradicating the underlying viral infection. This review provides a comparative analysis of current HPV prevention strategies and vaccination guidelines, as well as diagnostic and therapeutic recommendations for HPV-related diseases, including cutaneous warts, genital warts, laryngeal papillomatosis, cervical cancer, and HPV-related oropharyngeal cancers.
Review methods: To obtain the most up-to-date information and clinical guidelines, online scientific databases such as Mendeley and PubMed were utilized. Additionally, resources from the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), as well as websites of various professional medical societies, were consulted.
References
Nowakowski, A., Jach, R., Szenborn, L., Bidziński, M., Jackowska, T., Kotarski, J., et al. (2023). Recommendations of the Polish Society of Gynaecologists and Obstetricians [...] on prophylactic vaccinations against infections with human papillomaviruses in Poland. Ginekologia Polska, 94(9), 759–767. https://doi.org/10.5603/GP.a2022.0101
Bruni, L., Diaz, M., Castellsagué, X., Ferrer, E., Bosch, F. X., & de Sanjosé, S. (2010). Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases, 202(12), 1789–1799. https://doi.org/10.1086/657321
International Agency for Research on Cancer. (n.d.). Global Cancer Observatory. Cancer today – Cervical cancer incidence (heatmap). Retrieved August 7, 2025, from https://gco.iarc.fr/today/en/dataviz/maps-heatmap?mode=population&sexes=2&cancers=23&types=0
International Agency for Research on Cancer. (n.d.). Global Cancer Observatory. Cervical cancer mortality (heatmap).Retrieved August 7, 2025, from https://gco.iarc.fr/today/en/dataviz/maps-heatmap?mode=population&sexes=2&cancers=23&types=1
Zhang, J., Ke, Y., Chen, C., et al. (2025). HPV cancer burden by anatomical site, country, and region in 2022. Scientific Reports, 15, 21048. https://doi.org/10.1038/s41598-025-06700-8
Buck, C. B., Day, P. M., & Trus, B. L. (2013). The papillomavirus major capsid protein L1. Virology, 445(1–2), 169–174. https://doi.org/10.1016/j.virol.2013.05.038
Kombe Kombe, A. J., Li, B., Zahid, A., Mengist, H. M., Bounda, G. A., Zhou, Y., et al. (2021). Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Frontiers in Public Health, 8, 552028. https://doi.org/10.3389/fpubh.2020.552028
Jackowska, J., Piersiala, K., Klimza, H., & Wierzbicka, M. (2018). Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis – review of the literature. Otolaryngologia Polska, 72(4), 1–8. https://doi.org/10.5604/01.3001.0012.0484
World Health Organization. (2024). Considerations for human papillomavirus (HPV) vaccine product choice (2nd ed.). Geneva: WHO. https://creativecommons.org/licenses/by-nc-sa/3.0/igo/
World Health Organization. (2022). Human papillomavirus vaccines: WHO position paper (2022 update). Weekly Epidemiological Record, 97(50), 645–672. Retrieved August 7, 2025, from https://iorgaris.who.int/handle/10665/365351
World Health Organization. (2022). Human papillomavirus vaccines: WHO position paper, December 2022. Weekly Epidemiological Record, 97(50), 645–672.
Hoes, J., Pasmans, H., Knol, M. J., Donken, R., van Marm Wattimena, N., Schepp, R. M., et al. (2020). Persisting antibody response 9 years after bivalent human papillomavirus (HPV) vaccination in a cohort of Dutch women: Immune response and the relation to genital HPV infections. Journal of Infectious Diseases, 221(11), 1884–1894. https://doi.org/10.1093/infdis/jiaa007
Paraskevaidis, E., Athanasiou, A., Paraskevaidi, M., Bilirakis, E., Galazios, G., Kontomanolis, E., et al.; HeCPA Group. (2020). Cervical pathology following HPV vaccination in Greece: A 10-year HeCPA observational cohort study. In Vivo, 34(3), 1445–1449. https://doi.org/10.21873/invivo.11927
Herweijer, E., Feldman, A. L., Ploner, A., Arnheim Dahlström, L., Uhnoo, I., et al. (2015). The participation of HPV vaccinated women in a national cervical screening program: Population based cohort study. PLoS ONE, 10(7), e0134185. https://doi.org/10.1371/journal.pone.0134185
Thamsborg, L. H., Napolitano, G., Larsen, L. G., & Lynge, E. (2018). Impact of HPV vaccination on outcome of cervical cytology screening in Denmark – A register based cohort study. International Journal of Cancer, 143(7), 1662-1670. https://doi.org/10.1002/ijc.31568
Porras, C., Tsang, S. H., Herrero, R., Guillén, D., Darragh, T. M., Stoler, M. H., et al.; Costa Rica Vaccine Trial Group. (2020). Efficacy of the bivalent HPV vaccine against HPV-16/18-associated precancer: Long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncology, 21(12), 1643–1652. https://doi.org/10.1016/S1470-2045(20)30524-6
World Health Organization. (2024, March 5). Cervical cancer. Retrieved July 11, 2025, from https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020). Head and neck squamous cell carcinoma. Nature Reviews Disease Primers, 6(1), 92. https://doi.org/10.1038/s41572-020-00224-3
Wierzbicka, M., Józefiak, A., Szydłowski, J., et al. (2013). Recommendations for the diagnosis of human papilloma virus (HPV) high and low risk in the prevention and treatment of diseases of the oral cavity, pharynx and larynx. Guide of experts PTORL and KIDL. Otolaryngologia Polska, 67(3), 113–134.
World Health Organization. (n.d.). Immunization, vaccines and biologicals; HPV vaccine introduction clearing house; HPV dashboard. Retrieved July 11, 2025, from https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV)/hpv-clearing-house/hpv-dashboard
World Health Organization. (2024, March 5). Human papillomavirus and cancer. Retrieved July 11, 2025, from https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer
World Health Organization. (n.d.). HPV vaccine introduction clearing house: HPV dashboard. Retrieved July 11, 2025, from https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV)/hpv-clearing-house/hpv-dashboard
World Health Organization Regional Office for the Western Pacific. (2023). Strategic framework for the comprehensive prevention and control of cervical cancer in the Western Pacific Region 2023–2030. Manila: WHO. https://creativecommons.org/licenses/by-nc-sa/3.0/igo/
World Health Organization African Region. (n.d.). Status of the cervical cancer elimination initiative in WHO African Region. Retrieved July 11, 2025, from https://www.afro.who.int/publications/status-cervical-cancer-elimination-initiative-who-african-region
World Health Organization Regional Office for Europe. (2022). Roadmap to accelerate the elimination of cervical cancer as a public health problem in the WHO European Region 2022–2030. Copenhagen: WHO. https://creativecommons.org/licenses/by-nc-sa/3.0/igo/
Pan American Health Organization. (2025, January 8). 1999–2024 TAG recommendations for human papilloma virus (HPV). Retrieved July 11, 2025, from https://www.paho.org/en/documents/1999-2024-tag-recommendations-human-papilloma-virus-hpv
World Health Organization Regional Office for the Eastern Mediterranean. (2023). Regional cervical cancer elimination strategy for the Eastern Mediterranean. Cairo: WHO. https://creativecommons.org/licenses/by-nc-sa/3.0/igo/
World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention (2nd ed.). Geneva: WHO. https://creativecommons.org/licenses/by-nc-sa/3.0/igo/
Shastri, S. S., et al. (2022). Secondary prevention of cervical cancer: ASCO resource–stratified guideline update. JCO Global Oncology, 8, e2200217. https://doi.org/10.1200/GO.22.00217
Birdsong, G. G., & Davey, D. D. (2015). Specimen adequacy. In R. Nayar & D. Wilbur (Eds.), The Bethesda system for reporting cervical cytology (pp. 1–18). Cham: Springer. https://doi.org/10.1007/978-3-319-11074-5_1
Inturrisi, F., de Sanjosé, S., Desai, K. T., et al. (2024). A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study. International Journal of Cancer, 154(2), 241–250. https://doi.org/10.1002/ijc.34698
Ronco, G., et al. (2010). Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncology, 11(3), 249–257. https://doi.org/10.1016/S1470-2045(09)70360-2
Nasierowska-Guttmejer, A., Kędzia, W., Wojtylak, S., Lange, D., Rokita, W., Jach, R., & Wielgoś, M. (2016). Polish recommendations regarding diagnostics and treatment of cervical squamous intraepithelial lesions according to the CAP/ASCCP guidelines. Ginekologia Polska, 87(9), 670–676. https://doi.org/10.5603/GP.2016.0066
Narodowy Fundusz Zdrowia. (2025, June 30). Komunikat dla świadczeniodawców. Retrieved August 7, 2025, from https://www.nfz.gov.pl/aktualnosci/aktualnosci-centrali/komunikat-dla-swiadczeniodawcow,8796.html
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., et al. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1–187. https://doi.org/10.15585/mmwr.rr7004a1
Zhu, P., Qi, R. Q., Yang, Y., Huo, W., Zhang, Y., He, L., Wang, G., et al. (2022). Clinical guideline for the diagnosis and treatment of cutaneous warts (2022). Journal of Evidence-Based Medicine, 15(3), 284–301. https://doi.org/10.1111/jebm.12494
Salvo, G., Odetto, D., Pareja, R., Frumovitz, M., & Ramirez, P. T. (2020). Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. International Journal of Gynecological Cancer, 30(6), 873–878. https://doi.org/10.1136/ijgc-2020-001257
Cibula, D., et al. (2023). ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer – Update 2023. International Journal of Gynecological Cancer, 33(5), 649–666.
National Comprehensive Cancer Network. (2025, June 20). NCCN clinical practice guidelines in oncology: Head and neck cancers (Version 4.2025). Fort Washington, PA: NCCN.
Marur, S., et al. (2010). HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncology, 11(8), 781–789. https://doi.org/10.1016/S1470-2045(10)70017-6
Massarelli, E., William, W., Johnson, F., et al. (2019). Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: A phase 2 clinical trial. JAMA Oncology, 5(1), 67–73. https://doi.org/10.1001/jamaoncol.2018.4051
Mehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, B., Fulton Lieuw, T., et al.; De-ESCALaTE HPV Trial Group. (2019). Radiotherapy plus cisplatin or cetuximab in low risk human papillomavirus positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet, 393(10166), 51–60. https://doi.org/10.1016/S0140-6736(18)32752-1
Views:
82
Downloads:
26
Copyright (c) 2025 Aleksandra Kołdyj, Agnieszka Floriańczyk, Ewa Romanowicz, Agnieszka Ozdarska, Adrian Krzysztof Biernat, Marcin Lampart, Anna Rupińska, Hanna Skarakhdova, Kamila Krzewska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
